Literature DB >> 16513610

Microvessel density: correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas.

JianFei Guo1, Kotaro Higashi, Yoshimichi Ueda, Manabu Oguchi, Tsutomu Takegami, Hirohisa Toga, Tsutomu Sakuma, Hajime Yokota, Shogo Katsuda, Hisao Tonami, Itaru Yamamoto.   

Abstract

UNLABELLED: Although researched for many years, the prognostic value of tumor angiogenesis reflected by microvessel density (MVD) is still controversial, and there have been no previous reports regarding the correlation with 18F-FDG uptake in lung adenocarcinomas. Therefore, in the present study, we investigated the correlation between MVD determined with different endothelial cell antibodies and 18F-FDG uptake and compared the prognostic impact of those factors in lung adenocarcinomas.
METHODS: Forty-four patients with 45 lung adenocarcinomas underwent 18F-FDG PET before surgery. Consecutive paraffin-embedded sections obtained from each resected tumor were immunostained for CD31 (a panendothelial cell marker), CD105 (a proliferation-related endothelial cell marker), and CD34/alpha-SMA (for double labeling of endothelial cells and mural cells). Four high-power fields in the area with the highest MVD were selected for analysis. Computer-assisted image analysis was used to assess MVD.
RESULTS: MVD staining results for panendothelial cell markers can be classified into 3 microvessel patterns: diffuse, alveolar, and mixed. The highly ordered alveolar pattern is believed to represent preexisting alveolar vessels trapped in lung adenocarcinomas and may have no significant meaning for the aggressiveness of tumors. Preexisting alveolar cells also do not contribute to 18F-FDG uptake. CD105 staining of MVD (CD105-MVD) showed a significantly positive correlation with 18F-FDG uptake (P < 0.0001), whereas CD31 staining of MVD (CD31-MVD) showed a marginally negative correlation with it (P = 0.057). Although CD105-MVD correlated negatively with prognosis, patients with low CD105-MVD, compared with those with high or moderate CD105-MVD, had a much better prognosis in both disease-free and overall survival analyses (P = 0.017 and P = 0.013, respectively). Patients with low CD31-MVD had the worst prognosis (P = 0.032 for disease-free survival analysis and P = 0.179 for overall survival analysis).
CONCLUSION: There is no positive correlation between 18F-FDG uptake and MVD determined with panendothelial cell markers (CD31 and CD34); in contrast, there is a marginally negative correlation between them. MVD determined with CD105, which is a proliferation-related endothelial cell marker, reflects active angiogenesis, correlates positively with 18F-FDG uptake, and is a better indicator of prognosis in lung adenocarcinomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513610

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

1.  Imaging proliferation of ¹⁸F-FLT PET/CT correlated with the expression of microvessel density of tumour tissue in non-small-cell lung cancer.

Authors:  Wenfeng Yang; Yongming Zhang; Zheng Fu; Xiaorong Sun; Dianbin Mu; Jinming Yu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-12       Impact factor: 9.236

2.  Correlation of breast cancer subtypes, based on estrogen receptor, progesterone receptor, and HER2, with functional imaging parameters from ⁶⁸Ga-RGD PET/CT and ¹⁸F-FDG PET/CT.

Authors:  Hai-Jeon Yoon; Keon Wook Kang; In Kook Chun; Nariya Cho; Seock-Ah Im; Sunjoo Jeong; Song Lee; Kyeong Cheon Jung; Yun-Sang Lee; Jae Min Jeong; Dong Soo Lee; June-Key Chung; Woo Kyung Moon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-03-21       Impact factor: 9.236

3.  FDG-PET predicts survival in recurrent high-grade gliomas treated with bevacizumab and irinotecan.

Authors:  Cécile Colavolpe; Olivier Chinot; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Bequet-Boucard; Emeline Tabouret; Olivier Mundler; Dominique Figarella-Branger; Eric Guedj
Journal:  Neuro Oncol       Date:  2012-02-29       Impact factor: 12.300

Review 4.  Non-invasive imaging of angiogenesis in head and neck squamous cell carcinoma.

Authors:  Jacobus F A Jansen; Jason A Koutcher; Amita Shukla-Dave
Journal:  Angiogenesis       Date:  2010-04-11       Impact factor: 9.596

5.  The inhibition of Endostar on the angiogenesis and growth of gastrointestinal stromal tumor xenograft.

Authors:  Tian-bao Wang; Xiu-qing Wei; Wei-hao Lin; Han-ping Shi; Wen-guang Dong
Journal:  Clin Exp Med       Date:  2011-06-10       Impact factor: 3.984

6.  Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting.

Authors:  Hendra Budiawan; Gi Jeong Cheon; Hyung-Jun Im; Soo Jin Lee; Jin Chul Paeng; Keon Wook Kang; June-Key Chung; Dong Soo Lee
Journal:  Nucl Med Mol Imaging       Date:  2013-08-21

7.  Increased NDRG1 expression is associated with advanced T stages and poor vascularization in non-small cell lung cancer.

Authors:  Chuifeng Fan; Juanhan Yu; Yang Liu; Hongtao Xu; Enhua Wang
Journal:  Pathol Oncol Res       Date:  2010-09-18       Impact factor: 3.201

Review 8.  Imaging of tumor angiogenesis: functional or targeted?

Authors:  Baris Turkbey; Hisataka Kobayashi; Mikako Ogawa; Marcelino Bernardo; Peter L Choyke
Journal:  AJR Am J Roentgenol       Date:  2009-08       Impact factor: 3.959

9.  Assessement of angiogenesis reveals blood vessel heterogeneity in lung carcinoma.

Authors:  Amalia Birau; Raluca Amalia Ceausu; Anca Maria Cimpean; Pusa Gaje; Marius Raica; Teodora Olariu
Journal:  Oncol Lett       Date:  2012-09-05       Impact factor: 2.967

10.  Intratumoral Heterogeneous F-18 Fluorodeoxyglucose Uptake Corresponds with Glucose Transporter-1 and Ki-67 Expression in a Case of Krukenberg Tumor: Localization of Intratumoral Hypermetabolic Focus by Fused PET/MR Image.

Authors:  Hyung-Jun Im; Yong-Il Kim; Woo Ho Kim; Seung Hyup Kim; Keon Wook Kang
Journal:  Nucl Med Mol Imaging       Date:  2011-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.